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Background. Models of controlled human malaria infection (CHMI) initiated by mosquito bite have been widely used to assess
efﬁcacy of preerythrocytic vaccine candidates in small proof-of-concept phase 2a clinical trials. Efﬁcacy testing of blood-stage malaria
parasite vaccines, however, has generally relied on larger-scale phase 2b ﬁeld trials in malaria-endemic populations. We report the
use of a blood-stage P. falciparum CHMI model to assess blood-stage vaccine candidates, using their impact on the parasite mul-
tiplication rate (PMR) as the primary efﬁcacy end point.
Methods. Fifteen healthy United Kingdom adult volunteers were vaccinated with FMP2.1, a protein vaccine that is based on the
3D7 clone sequence of apical membrane antigen 1 (AMA1) and formulated in Adjuvant System 01 (AS01). Twelve vaccinees and 15
infectivity controls subsequently underwent blood-stage CHMI. Parasitemia was monitored by quantitative real-time polymerase
chain reaction (PCR) analysis, and PMR was modeled from these data.
Results. FMP2.1/AS01 elicited anti-AMA1 T-cell and serum antibody responses. Analysis of puriﬁed immunoglobulin G
showed functional growth inhibitory activity against P. falciparum in vitro. There were no vaccine- or CHMI-related safety concerns.
All volunteers developed blood-stage parasitemia, with no impact of the vaccine on PMR.
Conclusions. FMP2.1/AS01 demonstrated no efﬁcacy after blood-stage CHMI. However, the model induced highly reproducible
infection in all volunteers and will accelerate proof-of-concept testing of future blood-stage vaccine candidates.
Clinical Trials Registration. NCT02044198.
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The development of an effective vaccine against Plasmodium
falciparum malaria remains a key strategic goal to aid the con-
trol, local elimination, and eventual eradication of this disease
[1]. Next-generation vaccine strategies are currently seeking to
improve on the moderate levels of efﬁcacy reported from
phase 3 clinical trials of the RTS,S/AS01 malaria vaccine [2].
The complexity of the parasite’s life cycle within the vertebrate
host and mosquito vector has made the development of vac-
cines against malaria challenging but also offers opportunities
for numerous points of immune intervention [3]. One long-
standing strategy has been to develop vaccines against the path-
ogenic blood stage of P. falciparum by inducing antibodies
against the merozoite form of the parasite that invades erythro-
cytes [4]. Such vaccines could complement preerythrocytic im-
munity afforded by RTS,S/Adjuvant System 01 (AS01),
ameliorate disease severity, and/or reduce or prevent transmis-
sion by accelerating the control and clearance of blood-stage
parasitemia [5].
Numerous factors have hindered development of vaccines
against the merozoite, including substantial levels of polymor-
phism in candidate antigens, redundant erythrocyte invasion
pathways, and the apparent need for very high antibody concen-
trations to prevent rapid erythrocyte invasion [3, 4].Furthermore,
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the best approach to assess the efﬁcacy of blood-stage parasite
vaccines in humans has been widely debated [5]. Historically,
controlled human malaria infection (CHMI) models initiated
by mosquito bite have been widely used to assess efﬁcacy
of preerythrocytic vaccine candidates in small, proof-of-
concept, phase 2a clinical trials [6, 7]. In contrast, the efﬁcacy
testing of blood-stage vaccines has typically relied on larger-
scale phase 2b ﬁeld trials in endemic populations, although a
few trials of the mosquito-bite CHMI model have been per-
formed [8, 9]. Reasons for this include the assumption that
the efﬁcacy of blood-stage vaccines could not be assessed in
the short interval between parasite emergence from the liver
(around 6–7 days after mosquito bite) and diagnosis of
blood-stage infection by thick-ﬁlm microscopy (typically
4–6 days later).
CHMI models are being increasingly used for the testing of
antimalarial drugs [10], as well as vaccines [6]: infection can
now be initiated by mosquito bite, injection of cryopreserved
sporozoites, or injection of blood-stage parasites [6, 11–14]. A
growing number of P. falciparum strains are being tested, to
complement the historical focus on the laboratory reference
clone 3D7 (or its parental strain, NF54) [15, 16], and genetically
modiﬁed parasites have entered the clinical arena [17]. CHMI
studies are also being undertaken in malaria-endemic countries
[18, 19], and new models are being developed for Plasmodium
vivax [20].Here, we sought to build on previous experience [12–
14, 21, 22] and further develop the blood-stage P. falciparum
CHMI model to enable more-accurate and rapid efﬁcacy assess-
ment of blood-stage vaccine candidates prior to ﬁeld trial as-
sessment. The rationale for this study was that an effective
blood-stage vaccine should demonstrate a measurable effect
on the parasite multiplication rate (PMR) in malaria-naive in-
dividuals, especially against homologous challenge. Notably,
adults with naturally acquired immunity in a malaria-exposed
population showed substantially lower PMRs than nonimmune
United Kingdom adults [23]. PMR can be modeled for each in-
dividual on the basis of quantitative real-time polymerase chain
reaction (qPCR) data on blood-stage parasitemia prior to paten-
cy and detection by thick-ﬁlm microscopy [24]. This CHMI
model should allow for a longer period of qPCR monitoring,
homologous challenge, and, compared with the mosquito-bite
CHMI model, consistency in the initial number of blood-
stage parasites in all volunteers. The uniformity of the known
starting inoculum and the increased number of data points
available for modeling should also lead to improved conﬁdence
of the calculated PMRs and, thus, to greater power to observe
partial vaccine efﬁcacy [5, 13, 21].
Apical membrane antigen 1 (AMA1) has been a long-
standing vaccine antigen candidate, supported by a wealth of
data from immunoepidemiological and in vitro studies, as
well as rodent and nonhuman primate models [25]. A recombi-
nant protein vaccine, known as FMP2.1, based on the 3D7 clone
sequence of AMA1 [26] and formulated in AS01 or AS02 from
GlaxoSmithKline (GSK) has previously been developed and
tested in a series of phase 1a/b safety and immunogenicity trials
[8, 27–29]. Both adjuvants contain the immune enhancers
monophosphoryl lipid A and QS-21 Stimulon (Quillaja sapo-
naria Molina, fraction 21; licensed by GSK from Agenus). A
subsequent phase 2b ﬁeld trial involving 400 Malian children
that used the FMP2.1/AS02 formulation reported strain-speciﬁc
efﬁcacy against parasites with a 3D7 AMA1-like sequence in a
secondary efﬁcacy end point analysis [30]. Here, we report an
assessment of the PMR in healthy United Kingdom adults fol-
lowing FMP2.1/AS01 receipt and CHMI with homologous 3D7
clone blood-stage parasites in a phase 1/2a trial.
METHODS
FMP2.1/AS01 Vaccine
The protein vaccine FMP2.1 has been previously reported [26]
and encodes amino acids 83–531 of P. falciparum AMA1 (3D7
clone sequence). The batch of FMP2.1 protein was 130 months
old and passed repeat evaluation by all release assays prior to
use in this trial (Supplementary Table 1). As in previous trials
[8, 30], 50 µg of FMP2.1 was administered intramuscularly with
AS01.
Study Design and Approvals
The VAC054 study was an open-label, nonrandomized phase 1/
2a trial of the blood-stage malaria vaccine candidate FMP2.1/
AS01, with efﬁcacy assessed by blood-stage CHMI in vaccinated
volunteers and compared to that for infectivity controls (Sup-
plementary Figure 1). The vaccine was administered at days 0,
28, and 56 (nominal study days are reported throughout). Vol-
unteers underwent CHMI 2 weeks after the ﬁnal vaccination
(on day 70 or the day of challenge [dC + 0]). The study received
ethical approval from the United Kingdom National Health
Service (NHS) Research Ethics Service (Oxfordshire Research
Ethics Committee A, reference 13/SC/0596) and the Western
Institutional Review Board in the United States (reference
20131985). The study was approved by the United Kingdom
Medicines and Healthcare Products Regulatory Agency (refer-
ence 21584/0326/001-0001). The trial was registered with Clin-
caltrials.gov (NCT02044198) and was conducted according to
the principles of the current revision of the Declaration of
Helsinki 2008 and in full conformity with the International
Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use guidelines for
good clinical practice.
Participants
Healthy, malaria-naive males and nonpregnant females aged
18–45 years were invited to participate in the study. All volun-
teers gave written informed consent prior to participation. A
full list of inclusion and exclusion criteria is reported in Supple-
mentary Methods. The original donor of the blood-stage
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inoculum was seropositive for cytomegalovirus (CMV) and Ep-
stein-Barr virus (EBV), so in previous CHMI trials performed
in the United Kingdom [14, 21], volunteers were excluded on
the basis of CMV or EBV seronegativity [12, 13]. However,
the inoculum bank has tested negative for both viruses by
PCR, so, for this study, subjects were deemed eligible regardless
of serostatus. Data on adverse events (AEs) were collected
throughout a volunteer’s participation in the trial, either on
diary cards or at follow-up visits (Supplementary Table 2).
Blood-Stage CHMI
A single vial of blood-stage inoculum was thawed, washed, and
diluted under aseptic conditions (Supplementary Methods). Se-
quencing of the parasite gene encoding AMA1 was performed,
and 100% identity with the 3D7 clone sequence in the FMP2.1
vaccine was conﬁrmed. The intended inoculum was 1000 par-
asitized erythrocytes per volunteer. A limiting dilution assay
performed on the inoculum at the time the last volunteer was
infected demonstrated 69% viability (ie, an effective inoculum
of 690 parasites per volunteer). Following CHMI, blood samples
were collected once on dC + 1 and twice daily from dC + 2 for
qPCR analysis. Diagnosis of malaria was made on the basis of
positive ﬁndings on a thick blood ﬁlm, conﬁrmed by qPCR
ﬁndings of ≥500 parasites/mL (Supplementary Methods).
Parasite qPCR and PMR Modeling
qPCR was conducted as previously described [9], with some
minor modiﬁcations (Supplementary Methods). Raw data are
reported in Supplementary Table 3. qPCR data for 4 previous
mosquito-bite CHMI trials (MAL034A, MAL034B, VAC039,
and VAC045) have been previously reported [9, 31, 32]. PMR
was calculated using a linear model ﬁtted to log10-transformed
qPCR data [24] according to methods prespeciﬁed in the proto-
col (Supplementary Methods). Fitted lines were constrained to
pass through the known starting parasitemia level, calculated
from the results of the viability assay of the inoculum and a
weight-based estimate of each volunteer’s blood volume [9].
Ex Vivo Interferon γ (IFN-γ) Enzyme-Linked Immunspot (ELISpot) Assay
T-cell responses to AMA1 were assessed over time by ex vivo
IFN-γ ELISpot analysis following restimulation of peripheral
blood mononuclear cells (PBMCs) for 18–20 hours with over-
lapping peptides spanning the entire AMA1 3D7 sequence pre-
sent in the vaccine. Assays were performed as previously
described [9], with some minor modiﬁcations (Supplementary
Methods). Results are expressed as IFN-γ spot-forming units
(SFU) per million PBMCs.
Enzyme-Linked Immunosorbent Assay (ELISA) of Total Immunoglobulin
G (IgG), Avidity, and Isotypes
ELISAs of total AMA1 3D7 IgG in serum were performed in
Oxford as previously described, with reporting in micro-
grams/milliliter, using the same calibration-free concentration
analysis conversion factor [33]. Serum IgG ELISAs at the
National Institutes of Health (NIH) and the Walter Reed
Army Institute of Research (WRAIR) were also performed as
previously described, with reporting in micrograms/milliliter,
using conversion factors generated with afﬁnity-puriﬁed
AMA1-speciﬁc human IgG [8, 34]. Avidity (sodium thiocya-
nate–displacement) ELISA and isotype ELISAs were performed
in Oxford as previously described [33, 35].
In Vitro Assay of Growth Inhibitory Activity (GIA)
The ability of antibodies to inhibit growth of P. falciparum 3D7
clone parasites in vitro was assessed at the NIH GIA Reference
Center by a standardized GIA assay, using puriﬁed IgG as pre-
viously described [34]. Brieﬂy, each test IgG was incubated with
synchronized P. falciparum parasites for a single growth cycle,
and relative parasitemia levels were quantiﬁed by biochemical
determination of parasite lactate dehydrogenase. All samples
were tested at 10 mg/mL in a ﬁnal test well, followed by a dilu-
tion series for positive samples to determine the concentration
that gave 50% GIA (half maximal effective concentration
[EC50]). GIA assays were also conducted at the WRAIR, using
20% serum dilution as reported previously [8]. Serum IgG con-
centrations were measured using the ADI Human IgG ELISA
Kit (catalog no. 1750) as per the manufacturer’s protocol but
with the inclusion of an extra sample dilution (1:100 000).
Statistical Analysis
Full analyses are described in the Supplementary Methods. The
study was powered to detect a 33% decrease in mean PMR with
≥80% power.
RESULTS
Participant Flow
Forty-ﬁve volunteers were screened in total across 3 trial sites
(Supplementary Figure 1). Fifteen volunteers were recruited to
each group, with more males recruited than females in both
(group 1, 66.7% male; group 2, 73.3% male). The age range of
volunteers in group 1 was 23–43 years (mean, 33 years) and 19–
34 years in group 2 (mean, 22 years). Three volunteers in group
1 withdrew from the trial prior to completing the vaccination
phase, and 1 volunteer in group 1 also withdrew after CHMI
(at dC + 8.5), all for personal reasons.
Vaccine and CHMI Safety
There were no serious AEs or unexpected reactions during the
course of the trial, and no volunteers withdrew due to vaccine-
or CHMI-related AEs. The safety proﬁle of FMP2.1/AS01 was
similar to that reported previously in healthy US adult volunteers
[8], with the second and third vaccinations reported as more re-
actogenic than the ﬁrst. The solicited AEs are shown in Supple-
mentary Table 2. The majority of solicited AEs occurred within
the ﬁrst 2 days after vaccination and resolved within 72 hours.
There were no severe unsolicited AEs or laboratory-detected AEs
reported following vaccination. Symptoms relating to malaria par-
asite infection following CHMI were similar across both groups
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and peaked after initiation of antimalarial therapy. EBV and
CMV serological ﬁndings were checked before and after
CHMI, and, as expected, there were no cases of seroconversion
(Supplementary Table 4), adding to the growing safety database
that supports the use of this inoculum in volunteers regardless
of their EBV/CMV serostatus [12].
Blood-Stage CHMI and Vaccine Efﬁcacy
All volunteers developed patent blood-stage parasitemia follow-
ing CHMI and received a diagnosis on the basis of ﬁndings of
thick blood ﬁlm microscopy by dC + 10.5, except for the one
volunteer who withdrew on dC + 8.5 (Figure 1A and 1B and
Supplementary Figure 2A). This volunteer was asymptomatic,
and the thick blood ﬁlm was negative for parasites, so the vol-
unteer had not reached the criteria for commencing treatment;
however, the volunteer had positive qPCR results at the time of
withdrawal and was included in the primary analysis. There was
neither a delay to diagnosis in vaccinees as compared to con-
trols, nor any difference in parasitemia level between the groups
at time of diagnosis (Supplementary Figure 2B and 2C). The
protocol prespeciﬁed primary analysis for efﬁcacy was compar-
ison of PMR between the two groups. There was no difference
in the mean PMRs between the two groups (Figure 1C). The
mean PMR (±SD) for group 1 was 10.32 ± 2.13 (95% conﬁdence
interval [CI], 8.97–11.67) and for group 2 was 10.31 ± 2.36
(95% CI, 9.00–11.62; P = .99, by the 2-tailed unpaired t test).
T-Cell and Antibody Responses in Vaccinees and Controls
FMP2.1/AS01 elicited T-cell responses as assessed by ex vivo
IFN-γ ELISpot, with median responses of 577 and 396 SFU/
million PBMCs at d42 and d69/C-1 respectively (Figure 2A
and Supplementary Figure 3A). These responses did not boost
after the CHMI, with a median of 148 SFU/million PBMCs seen
at d98/C+28. Modest responses were induced in the controls
(median, 29 SFU/million PBMCs at the same time point),
with only 2 volunteers showing responses >150 SFU/million
PBMCs (Figure 2B and Supplementary Figure 3B–D).
AMA1-speciﬁc serum IgG responses were measured by ELISA
in Oxford, with median responses of 85 and 97 µg/mL at d42 and
d69/C-1, respectively (Figure 2C and Supplementary Figure 4A).
These responses did not boost after CHMI, with a median of 56
µg/mL seen at d98/C+28. Only 1 of 15 controls showed a de novo
anti-AMA1 IgG response at d98/C+28 (59 µg/mL; Figure 2D and
Supplementary Figure 4B–D). Findings of 2 independent ELISAs
(performed at the NIH and WRAIR) correlated with ﬁndings of
Oxford’s ELISA but were not concordant (Supplementary Fig-
ure 5A and 5B), with median responses of 114 and 295 µg/mL
at d69/C-1, respectively (Supplementary Figure 5C and 5D).
Figure 1. Blood-stage controlled human malaria infection and parasite multiplication rate (PMR) analysis. Individual quantitative polymerase chain reaction data are shown
for the VAC054 phase 2a study, including 12 apical membrane antigen 1 (AMA1) vaccinees (group 1; A) and 15 unvaccinated infectivity controls (group 2; B). The lower limit of
quantification is indicated by the dotted line at 20 parasites/mL. C, Primary end point analysis of PMRs, showing data for each individual plus the mean ± SD for each group.
Both data sets are normally distributed (as determined by the D’Agostino–Pearson test), with similar variance (P = .74, by the F test).
1746 • JID 2016:213 (1 June) • Payne et al
 at Im
perial College London on A
ugust 4, 2016
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
The results from WRAIR were signiﬁcantly lower than those re-
ported by Spring et al for the same vaccine tested in healthy US
adults (Supplementary Figure 5E) [8]. The avidity of the anti-
AMA1 IgG was similar at d42, d69/C-1, and after CHMI in
the vaccinees (Supplementary Figure 6A) and very similar to
that observed with other AMA1 vaccines in humans [33, 35].
The response was composed of IgG1, IgG3, immunoglobulin
A, and immunoglobulin M, and this proﬁle was not affected by
CHMI (Supplementary Figure 6B).
Measures of In Vitro GIA
Serum was analyzed at the GIA Reference Center at the NIH,
and IgG was puriﬁed from each sample. Samples from group
1 volunteers prior to vaccination (d0) and group 2 volunteers
prior to CHMI (d69/dC-1) did not demonstrate any GIA
above baseline. Samples from group 1 volunteers following 3
vaccinations demonstrated a median in vitro GIA of 59.5%
(range, 38.5%–86.5%), with 10 mg/mL puriﬁed IgG at dC-1
(Figure 3A). The GIA decreased as puriﬁed IgG was diluted
(Figure 3B) and was related to the AMA1-speciﬁc IgG concen-
tration (Figure 3C), in close agreement with other independent
studies [33, 34]. The EC50 was calculated for each puriﬁed IgG,
with a median of 8.1 mg/mL. To relate these results (using a
normalized concentration of puriﬁed IgG) back to the original
sera, the concentration of IgG in each original serum sample
was also measured. This enabled calculation of the GIA50
serum titer, deﬁned previously as the dilution factor of each
serum sample required to reach the concentration of puriﬁed
IgG that gives 50% GIA [36]. The median GIA50 titer for
group 1 was 1.5, with the maximum observed being a dilution
factor of 3.0 (Figure 3D). Analyses of GIA, using 20% serum,
were also conducted at WRAIR. These results were comparable
to those observed in the NIH assay at approximately 2 mg/mL
puriﬁed IgG (equivalent to 20% serum) but signiﬁcantly lower
than those reported by Spring et al for the same vaccine tested
in healthy US adults [8] (Supplementary Figure 7).
Comparison of Blood-Stage and Mosquito-Bite CHMI
The PMRs in the group 2 infectivity controls were compared to
historical data from unvaccinated infectivity control volunteers
in 4 previous CHMI trials, in which volunteers were exposed to
the bites of 5 mosquitoes infected with the 3D7 clone of P. fal-
ciparum [9, 31, 32]. PMRs were modeled from these data sets as
described in Supplementary Methods. The pooled data from the
Figure 2. T-cell and antibody responses in vaccinees and controls. A and B, T-cell responses were assessed in each group by ex vivo interferon γ (IFN-γ) enzyme-linked
immunospot analysis, using fresh peripheral blood mononuclear cells (PBMCs). C and D, Serum anti–apical membrane antigen 1 (AMA1; 3D7) immunoglobulin G (IgG) re-
sponses were assessed in Oxford for each group by an enzyme-linked immunosorbent assay. Mean and individual responses are shown over time. Blood-stage controlled human
malaria infection took place on day 70. Abbreviation: SFU, spot-forming units.
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4 trials showed a similar mean PMR of 10.23 per 48 hours
(n = 21) to blood-stage CHMI, but a signiﬁcantly larger spread
(SD = 4.67; P = .008, by the F test; Figure 4A). These data indi-
cated that the blood-stage model provides better power to ob-
serve partial vaccine efﬁcacy against blood-stage parasite
growth rates and, moreover, showed that each individual
PMR can be modeled from the qPCR data with greater conﬁ-
dence (Figure 4B).
DISCUSSION
A suitable means to assess proof-of-concept vaccine efﬁcacy
against blood-stage P. falciparum has been widely debated [5].
It has been argued that blood-stage vaccines may prevent disease
phenotypes and/or impart immune-mediated protection only at
high parasite densities. In these cases, CHMI in healthy malaria-
naive adult volunteers would not be suitable because volunteers
would require rescue treatment at the time of microscopy-based
patency, even when this is prior to the onset of disease symptoms.
However, in an era when next-generation vaccines are seeking to
build on the success of RTS,S [1, 2], it is vital that a blood-stage
vaccine candidate be able to control parasitemia in a malaria-
naive individual and prevent onset of disease symptoms. Here
we sought to develop the blood-stage CHMI model in healthy
United Kingdom adults to address this concept, using the effect
on PMR as the primary efﬁcacy end point.
Although AMA1 has long been considered a leading candi-
date vaccine antigen [25], signiﬁcant efﬁcacy has not been dem-
onstrated as a primary end point of any phase 2a/b clinical trial
[4]. Previous CHMI trials initiated by mosquito bite have sug-
gested that some preerythrocytic immunity can be afforded by
vaccines encoding AMA1 alone [8, 9] or in combination with
circumsporozoite protein [37] (which associated with CD8+
T-cell responses against AMA1 [38]), but no direct impact on
blood-stage parasitemia has been observed [14]. Nevertheless,
in a phase 2b ﬁeld trial in Malian children, FMP2.1/AS02 had
an efﬁcacy of 64.3% (hazard ratio, 0.36; 95% CI, .08–.86; P = .03)
in a predeﬁned secondary analysis against clinical malaria with
3D7-type parasites (deﬁned by 8 immunologically important
AMA1 polymorphisms in the cluster 1 loop of domain I), al-
though the number of cases meeting this deﬁnition was small
[30, 39].This allele-speciﬁc efﬁcacy, seen in the ﬁrst malaria sea-
son, did not extend into the second season of follow-up [40].
Figure 3. Assessment of functional growth inhibitory activity (GIA) induced by FMP2.1/Adjuvant System 01 vaccination. A, In vitro GIA of purified immunoglobulin G (IgG)
was assessed at 10 mg/mL against 3D7 clone Plasmodium falciparum parasites at the National Institutes of Health (NIH) GIA Reference Center. Individual data and medians are
shown for each group on the day before challenge (dC-1), as well as before vaccination (d0) for group 1. Responses >12% are typically regarded as positive for 3D7. B Dilution
series of purified IgG from group 1 samples obtained on dC-1. C, Relationship between GIA and anti-3D7 AMA1 serum IgG concentrations, measured by enzyme-linked im-
munosorbent assay (ELISA) at the NIH. A nonlinear regression curve is also shown (n = 60). The level of anti-3D7 AMA1 response in this ELISA that gives 50% GIA (GIA50),
indicated by the dotted line, was 75.5 µg/mL, (95% confidence interval, 68.3–84.2). D, Individual half maximal effective concentration (EC50) for each purified IgG is shown, as
well as the GIA50 titers. Individual data and medians are shown for group 1 at dC-1.
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Here we used the blood-stage CHMI model to assess FMP2.1/
AS01 against homologous 3D7 clone parasites. In this trial,
FMP2.1/AS01 did not demonstrate any efﬁcacy, with no reduc-
tion in PMR in vaccinees, compared with the infectivity control
group. However, this trial demonstrated the reproducibility of
the blood-stage CHMI model, with much larger group sizes
than used in previous studies [14, 21, 22]. Moreover, we demon-
strate its usefulness for measuring modest reductions in PMR in
comparison to mosquito-bite CHMI, where analysis of histori-
cal data showed a higher dispersion of data in the infectivity
controls.
FMP2.1/AS01 was immunogenic in this trial, eliciting
AMA1-speciﬁc T-cell and antibody responses. IFN-γ T-cell re-
sponses, measured by ELISpot analysis, were higher than those
seen with other AMA1 protein-in-adjuvant vaccines tested
using the same assay [14]. Puriﬁed serum IgG was able to inhib-
it parasite growth in vitro at high levels at 10 mg/mL, but both
the ELISA and functional GIA analysis performed at WRAIR
showed the responses to be modestly but signiﬁcantly lower
than those reported in a previous trial of this vaccine in healthy
US adults that used AS01 and AS02 [8]. The serum antibody
and GIA responses were also comparable to those for another
AMA1 vaccine candidate that failed to impact PMR in a
much smaller and underpowered blood-stage CHMI trial
[14]. The somewhat reduced immunogenicity in this trial may
have been related to the age of the FMP2.1 protein, but there
had been no measurable change in the protein quality over
time, and the vaccine lot passed all rigorous quality control test-
ing prior to use in this study. Nevertheless, the lack of FMP2.1/
AS01 efﬁcacy in this trial, in contrast to ﬁndings from the phase
2b ﬁeld study, could be due to a number of possible reasons: re-
duced vaccine immunogenicity, the use of AS01 instead of
AS02, an impact of this vaccine only at high parasite densities,
a preerythrocytic effect of the vaccine, or the fact that the Ma-
lian children, unlike United Kingdom adults, would have pos-
sessed preexisting antimalarial immune responses, including
anti-AMA1 IgG, which may have acted in conjunction with
the vaccine-induced anti-AMA1 responses.
Irrespective of this result, the immunogenicity analyses from
this trial have highlighted important directions for future re-
search. First, there is a need to harmonize immunomonitoring
analyses between laboratories, in particular with regard to the
reporting of antibody concentrations in µg/mL. Work is cur-
rently ongoing between the 3 laboratories to address this
issue. More importantly, these data indicate that vaccines devel-
oped on the basis of the GIA assay in the future will need to
Figure 4. Comparison of blood-stage and mosquito-bite controlled human malaria infection (CHMI). A, Parasite multiplication rates (PMRs) were calculated for infectivity
control volunteers in 4 historical mosquito-bite CHMI trials ( purple). Data are shown for each trial and are also pooled. Individual data points and mean ± SD are shown. B,
Individual PMRs and 95% confidence intervals are shown.
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achieve >40% GIA at 2.5 mg/mL puriﬁed IgG (in the NIH GIA
Reference Center assay) if they are to protect a malaria-naive
human. Notably, these trial results are consistent with previous-
ly reported data from Aotus monkeys [36, 41], including one
trial in which only vaccinated animals that achieved >60%
GIA using a puriﬁed IgG concentration of 2.5 mg/mL, or a
GIA50 titer >5, were protected against blood-stage challenge
[36]. These data thus support the clinical development of new
vaccines with quantitatively or qualitatively improved antimer-
ozoite antibody responses that may function by GIA or other
mechanisms [42, 43]. The blood-stage CHMI model, as report-
ed here, should accelerate proof-of-concept testing of this next
generation of blood-stage malaria vaccine candidates and could
potentially be used for testing passive immunization regimens
that use puriﬁed IgG or monoclonal antibodies, as are being
developed for human immunodeﬁciency virus [44].
Supplementary Data
Supplementary materials are available at http://jid.oxfordjournals.org.
Consisting of data provided by the author to beneﬁt the reader, the posted
materials are not copyedited and are the sole responsibility of the author, so
questions or comments should be addressed to the author.
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